The new product, a "wound gel", seems to be an interesting one because it is a purchase of certain rights, and the press release doesn't say what hitk paid for it. When they file an SEC report on it, maybe that will say.
I add that Canaccord, in its initial release, said that hitk was "grinding it out" (or words to that effect). That is what they are continuing to do. I am still surprised that the flonase competition announcement hasn't hurt more, but we will see what the next cc or earnings report tells us - maybe they can continue to grind it out also on flonase, and preserve this nice income stream.